Search Result
Results for "
vasoconstriction
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-17352
-
Ro 61-1790; VML 588; AXV-034343
|
Endothelin Receptor
|
Cardiovascular Disease
|
Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction .
|
-
-
- HY-B1298
-
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
Methoxamine hydrochloride is a selective alpha1-adrenergic receptor agonist. Methoxamine hydrochloride causes vasoconstriction and increased peripheral vascular resistance . Methoxamine hydrochloride significantly increased the overflow of ATP, ADP and AMP, but not adenosine, by a prazosin-sensitive mechanism in the rabbit pulmonary artery .
|
-
-
- HY-B1546A
-
Benzylamiloride hydrochloride
|
Na+/Ca2+ Exchanger
Sodium Channel
|
Neurological Disease
|
Benzamil hydrochloride (Benzylamiloride hydrochloride), an Amiloride analogue, is a Na +/Ca 2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil hydrochloride also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil hydrochloride inhibits TRPP3-mediated Ca 2+-activated currents, with an IC50 of 1.1 μM .
|
-
-
- HY-17034
-
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
Medetomidine is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine has sedative and analgesic effects. Medetomidine can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .
|
-
-
- HY-17352A
-
Ro 61-1790 disodium; VML 588 disodium; AXV-034343 disodium
|
Endothelin Receptor
|
Cardiovascular Disease
|
Clazosentan disodium (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan disodium inhibits ET-1-mediated vasoconstriction. Clazosentan disodium prevents cerebral vasospasm, vasospasm-related cerebral infarction .
|
-
-
- HY-B1298A
-
|
Adrenergic Receptor
|
Cardiovascular Disease
|
Methoxamine is a selective alpha1-adrenergic receptor agonist. Methoxamine causes vasoconstriction and increased peripheral vascular resistance . Methoxamine hydrochloride significantly increased the overflow of ATP, ADP and AMP, but not adenosine, by a prazosin-sensitive mechanism in the rabbit pulmonary artery .
|
-
-
- HY-D1501
-
|
Fluorescent Dye
|
Others
|
Fura PE-3 potassium is a Ca 2+sensitive fluorophore. Fura PE-3 potassium loads in IPA (intrapulmonary arteries) and MA (mesenteric resistance arteries) for the research of vasoconstriction .
|
-
-
- HY-134370
-
|
P2X Receptor
|
Cardiovascular Disease
|
Ap4G is a dinucleoside polyphosphate compound with vasoconstrictor activity. Ap4G regulates vasoconstriction through P2 receptors, especially P2X receptors, and is an important tool for studying vascular physiology and pathology .
|
-
-
- HY-112824
-
|
Angiotensin Receptor
|
Cardiovascular Disease
|
L-162313 is a non-peptide angiotensin II AT1 and AT2 receptor agonist, with IC50 values of 1.1 and 2.0 nM for AT1 and AT2 receptor, respectively. L-162313 can be used for the research of vasoconstriction, aldosterone release, and cardiovascular growth .
|
-
-
- HY-B1546
-
Benzylamiloride
|
Na+/Ca2+ Exchanger
Sodium Channel
|
Neurological Disease
|
Benzamil (Benzylamiloride), an Amiloride analogue, is a Na +/Ca 2+ exchanger (NCX) inhibitor (IC50~100 nM). Benzamil also is a non-selective Deg/epithelial sodium channels (ENaC) blocker, and can potentiate myogenic vasoconstriction. Benzamil inhibits TRPP3-mediated Ca 2+-activated currents, with an IC50 of 1.1 μM .
|
-
-
- HY-17034B
-
MPV785
|
Adrenergic Receptor
|
Neurological Disease
Endocrinology
|
Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .
|
-
-
- HY-106123
-
|
Angiotensin Receptor
|
Cardiovascular Disease
|
Pomisartan is an orally active angiotensin II receptor type AT1 antagonist (IC50=0.26 μM). Pomisartan works by inhibiting the binding of angiotensin II to the AT1 receptor, thereby blocking the vasoconstriction and aldosterone release caused by this interaction. Pomisartan results in a blood pressure-lowering effect .
|
-
-
- HY-113654
-
|
TRP Channel
|
Others
|
AMG 7905 is a hypothermia-inducing transient receptor potential vanilloid type 1 (TRPV1) antagonist. AMG 7905 potentiates TRPV1 channels activation by protons and drives the reflectory inhibition of thermogenesis and tail-skin vasoconstriction, while potently blocking channel activation by capsaicin .
|
-
-
- HY-111326
-
-
-
- HY-111326A
-
-
-
- HY-130304
-
iPE2-III
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
8-Isoprostaglandin E2 (iPE2-III) is a member of the isoprostane class of prostanoids. 8-Isoprostaglandin E2 acts at the receptor for thromboxane A2 (the TP) in vivo to induce vasoconstriction and platelet aggregation. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway .
|
-
-
- HY-116680
-
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves .
|
-
-
- HY-B0446
-
Naphthazoline hydrochloride
|
Adrenergic Receptor
TNF Receptor
Interleukin Related
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Naphazoline (Naphthazoline) hydrochloride is a potent α-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research .
|
-
-
- HY-111326AR
-
|
Adrenergic Receptor
TNF Receptor
Interleukin Related
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
|
Naphazoline (nitrate) (Standard) is the analytical standard of Naphazoline (nitrate). This product is intended for research and analytical applications. Naphazoline (Naphthazoline) nitrate is an α-adrenergic receptor agonist. Naphazoline nitrate reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline nitrate reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline nitrate can be used for non-bacterial conjunctivitis research .
|
-
-
- HY-P1016
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
|
-
-
- HY-B0446R
-
|
Adrenergic Receptor
TNF Receptor
Interleukin Related
VEGFR
|
Cardiovascular Disease
Inflammation/Immunology
|
Naphazoline (hydrochloride) (Standard) is the analytical standard of Naphazoline (hydrochloride). This product is intended for research and analytical applications. Naphazoline (Naphthazoline) hydrochloride is a potent α-adrenergic receptor agonist. Naphazoline hydrochloride reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline hydrochloride reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF。Naphazoline hydrochloride can be used for non-bacterial conjunctivitis research .
|
-
-
- HY-P1016B
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research . .
|
-
-
- HY-113350
-
TXA2
|
Prostaglandin Receptor
Endogenous Metabolite
|
Inflammation/Immunology
Endocrinology
Cancer
|
Thromboxane A2 (TXA2) is a prostanoid mediator produced by the metabolism of Arachidonic acid (HY-109590) through the cyclooxygenase pathway. Thromboxane A2 activates the thromboxane-prostanoid (TP) receptors. Thromboxane A2 is a potent vasoconstrictor eicosanoid. Thromboxane A2 (TXA2) leads to potent vasoconstriction by stimulation of smooth muscle cells. Thromboxane A2 acts as s tonic immunoregulator to regulate adaptive immune responses .
|
-
-
- HY-B0556A
-
Tetryzoline hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion .
|
-
-
- HY-B0556
-
Tetryzoline
|
Adrenergic Receptor
|
Cardiovascular Disease
|
Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion .
|
-
-
- HY-B0556B
-
Tetryzoline nitrate
|
Adrenergic Receptor
|
Cardiovascular Disease
Metabolic Disease
|
Tetrahydrozoline (Tetryzoline) nitrate , a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion .
|
-
-
- HY-102029
-
SRTX-c
|
Endothelin Receptor
|
Cardiovascular Disease
|
Sarafotoxin S6c (SRTX-c) is a potent endothelin-B receptor agonist. Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels .
|
-
-
- HY-131545
-
NT-702 free base; NT-702 free base
|
Others
|
Others
|
Parogrelil (NT-702 free base) is a compound with intermittent claudication inhibitory activity that inhibits PDE3, inhibits platelet aggregation and vasoconstriction, and improves walking distance and plantar surface temperature in a rat experimental model.
|
-
-
- HY-B0556AS
-
Tetryzoline-d4 (hydrochloride)
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
Tetrahydrozoline-d4 (hydrochloride) is the deuterium labeled Tetrahydrozoline hydrochloride. Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion[1][2].
|
-
-
- HY-P10291
-
-
-
- HY-B0556R
-
|
Adrenergic Receptor
|
Cardiovascular Disease
|
Tetrahydrozoline (Standard) is the analytical standard of Tetrahydrozoline. This product is intended for research and analytical applications. Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion .
|
-
-
- HY-B0556AR
-
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
|
Tetrahydrozoline (hydrochloride) (Standard) is the analytical standard of Tetrahydrozoline (hydrochloride). This product is intended for research and analytical applications. Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion .
|
-
-
- HY-114666
-
NDR-5523A
|
Others
|
Cardiovascular Disease
|
Trimoxamine hydrochloride (NDR-5523A) is an antihypertensive drug with hypotensive activity. Trimoxamine hydrochloride can be used to inhibit hypertension-related diseases. Trimoxamine hydrochloride lowers blood pressure by inhibiting vasoconstriction. Trimoxamine hydrochloride plays an important role in the management of cardiovascular diseases .
|
-
-
- HY-113042
-
|
Endogenous Metabolite
|
Cardiovascular Disease
Endocrinology
|
Prostaglandin B2 is a prostaglandin. Prostaglandin B2 is the main substance in cord blood mesenchymal stem cells, to inhibit DC-T Cell proliferation. Prostaglandin B2 also induces cutaneous vasoconstriction of the canine hind paw .
|
-
-
- HY-N8251
-
-
-
- HY-124150
-
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
BM567 is a sulfonylurea compound (compound 1), which exhibits antithrombogenic efficacy as thromboxane A2 receptor (TXR) antagonists and thromboxane A2 synthase (TXS) inhibitors, with IC50s of 1.1 and 12 nM, respectively .
|
-
-
- HY-131395
-
N-Acetyl-LTE4
|
Endogenous Metabolite
|
Cardiovascular Disease
|
N-Acetyl-Leukotriene E4 (N-Acetyl-LTE4) is a metabolite of Leukotriene E4 (LTE4) (HY-113465), which is detected in bile and urine . N-Acetyl-Leukotriene E4 produces a vasoconstriction in the mesenteric vessels which led to reduction of blood flow to the gut .
|
-
-
- HY-17034BS1
-
MPV785-13C,d3
|
Isotope-Labeled Compounds
Adrenergic Receptor
|
Endocrinology
|
Medetomidine-13C,d3 (hydrochloride) is a deuterated labeled Medetomidine (hydrochloride) . Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .
|
-
-
- HY-160210
-
|
Adrenergic Receptor
|
Cardiovascular Disease
|
BAY-6096 is a potent, selective, and highly water-soluble adrenergic receptor α2B antagonist with an IC50 of 14 nM. BAY-6096 can effectively reduceα 2B receptor agonist-induced rat vascular contraction .
|
-
-
- HY-120535
-
-
-
- HY-P1019
-
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
[Ala1,3,11,15]-Endothelin (53-63) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) has selectivity for ET B with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) can be used for the research of vasoconstriction
|
-
-
- HY-P1019A
-
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
[Ala1,3,11,15]-Endothelin (53-63) (TFA) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) (TFA) has selectivity for ET B with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) (TFA) can be used for the research of vasoconstriction .
|
-
-
- HY-121311
-
|
Serotonin Transporter
Adrenergic Receptor
|
Cardiovascular Disease
|
Metrenperone is an inhibitor for 5-HT2 receptor. Metrenperone exhibits α1 and α2 antagonist activity as well as anti-H1 and anti-dopaminergic efficacy. Metrenperone can lower the blood pressure, enhances bradycardia in peripheral ischemia, inhibits serotonin-induced platelet aggregation, and antagonizes serotonin-mediated vasoconstriction. Metrenperone promotes the repair of acutely damaged collagen tissue .
|
-
-
- HY-13527
-
|
5-HT Receptor
|
Cardiovascular Disease
Neurological Disease
|
LY310762 is a selective 5-HT1D receptor antagonist (Ki=249 nM) with a weak affinity for 5-HT1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of 5-HTSumatriptan (HY-B0121B)-induced decrease in excitatory postsynaptic potential (EPSC) amplitude .
|
-
-
- HY-137606
-
UP4A
|
P2X Receptor
|
Cardiovascular Disease
|
Uridine adenosine tetraphosphate (UP4A) is an endothelium-derived vasoconstrictor that primarily acts through the P2X1 receptor and possibly through the P2Y2 and P2Y4 receptors. Uridine adenosine tetraphosphate can be used in the study of cardiovascular diseases .
|
-
-
- HY-101607A
-
|
Calcium Channel
|
Cardiovascular Disease
|
KT-362 free acid is an intracellular calcium antagonist with antiarrhythmic and vasodilatory effects. KT-362 free acid shows an antagonistic effect against norepinephrine (NE) induced vasoconstriction response, achieved by reducing inositol phospholipid hydrolysis, thereby reducing intracellular calcium mobilization. KT-362 free acid can be used to study the contraction and relaxation mechanisms of vascular smooth muscle, especially in exploring the role of intracellular calcium mobilization and inositol phospholipid hydrolysis in vascular contraction .
|
-
-
- HY-135283
-
A-216546
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
ABT-546 (A-216546) is a potent, highly selective and active endothelin ETA receptor antagonist with a Ki of 0.46 nM for [ 125I]endothelin-1 binding to cloned human endothelin ETA. ABT-546 is >25,000-fold more selective for the ETA receptor than for the ETB receptor. ABT-546 blocks endothelin-1-induced arachidonic acid release and phosphatidylinositol hydrolysis with IC50 of 0.59 nM and 3 nM, respectively .
|
-
-
- HY-101390
-
(S)-Niguldipine hydrochloride
|
Calcium Channel
|
Cardiovascular Disease
|
(+)-Niguldipine hydrochloride is an antagonist for calcium channel. (+)-Niguldipine hydrochloride produces vasodilation by blocking calcium channels and reducing the transmembrane influx of calcium ions. (+)-Niguldipine hydrochloride inhibits U-46619 (HY-108566)-induced coronary vasoconstriction in guinea pig Langendorff heart with pID50 of 11.37, binds to calcium channel on guinea pig skeletal muscle membrane with Ki of 9.75, and lowers the blood pressure in spontaneously hypertensive rat with pED30 of 7.1. (+)-Niguldipine hydrochloride ameliorates cardiovascular diseases such as hypertension, angina pectoris and arrhythmias .
|
-
-
- HY-137355
-
15(S)-15-Methyl PGD2
|
Prostaglandin Receptor
|
Metabolic Disease
|
15(S)-15-methyl Prostaglandin D2 (15(S)-15-methyl PGD2) is a metabolically stable synthetic analog of PGD2. In contrast to PGD2, 15(S)-15-methyl PGD2 induces vasoconstriction and increases systemic blood pressure with much reduced inhibitory activity on ADP-induced platelet aggregation. It also exhibits strong antifertility activity in hamsters (200-fold more potent than PGD2).
|
-
-
- HY-12554
-
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Terlipressin is a vasopressin analogue with potent vasoactive properties. Terlipressin is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin exerts anti-inflammatory and anti-oxidative effects. Terlipressin has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-12554A
-
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-12554B
-
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P2141A
-
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P2141
-
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-132184
-
5,6-EET; (±)5,6-EpETrE
|
Adrenergic Receptor
|
Endocrinology
|
5,6-Epoxyeicosatrienoic acid (5,6-EET; (±)5,6-EpETrE) is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5,6-Epoxyeicosatrienoic acid degrades into 5,6-DiHET and 5,6-δ-lactone, which can be converted to 5,6-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5,6-Epoxyeicosatrienoic acid has been implicated in the mobilization of calcium and hormone secretion. 5,6-Epoxyeicosatrienoic acid is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50=0.54 μM), and Cav3. and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 μM. In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 μM. (±)5,6-Epoxyeicosatrienoic acid is provided as a mixture of the free acid and lactone.
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1016B
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
BQ-3020 ammonium is a selective endothelin receptor (ETB receptor) agonist. BQ-3020 ammonium inhibits [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 ammonium elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 ammonium makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research . .
|
-
- HY-102029
-
SRTX-c
|
Endothelin Receptor
|
Cardiovascular Disease
|
Sarafotoxin S6c (SRTX-c) is a potent endothelin-B receptor agonist. Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels .
|
-
- HY-12554A
-
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Terlipressin diacetate is a vasopressin analogue with potent vasoactive properties. Terlipressin diacetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin diacetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin diacetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P3765
-
|
Peptides
|
Cardiovascular Disease
|
Auriculin A is a synthetic atrial natriuretic factor (ANF) with hemodynamic effect. Auriculin A antagonizes renal vasoconstriction in the dog, and influences on arterial baroreflex control of heart rate, systemic blood pressure, and perfusion pressure in the hind limb (perfused at constant flow) in rabbits .
|
-
- HY-P1016
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
BQ-3020 is a selective endothelin receptor (ETB receptor) agonist that displaces [ 125I] ET-1 binding to ETB receptors, with an IC50 value of 0.2 nM. BQ-3020 elicits vasoconstriction in the rabbit pulmonary artery. BQ-3020 makes relaxation of the pig urinary bladder neck and can be used for cardiovascular disease research 1 2.
|
-
- HY-P10291
-
-
- HY-P1019
-
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
[Ala1,3,11,15]-Endothelin (53-63) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) has selectivity for ET B with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) can be used for the research of vasoconstriction
|
-
- HY-P1019A
-
|
Endothelin Receptor
|
Cardiovascular Disease
Endocrinology
|
[Ala1,3,11,15]-Endothelin (53-63) (TFA) is an ETB agonist. [Ala1,3,11,15]-Endothelin (53-63) (TFA) has selectivity for ET B with IC50 values range from 0.33 nM to 0.61 nM. [Ala1,3,11,15]-Endothelin (53-63) (TFA) can be used for the research of vasoconstriction .
|
-
- HY-P3565
-
STX-b
|
Peptides
|
Cardiovascular Disease
|
Sarafotoxin S6d (STX-b) is a polypeptide toxin isolated from the venom of the Israeli sand boa constrictor. Sarafotoxin S6d induces multiple electrocardiogram (ECG) changes including myocardial ischemia and hyperkalemia. Sarafotoxin S6d induces strong extracellular calcium-dependent vasoconstriction in rat aorta and exhibits positive inotropic effects in rat atria. Sarafotoxin S6d can be used in the study of cardiovascular diseases .
|
-
- HY-12554B
-
|
Vasopressin Receptor
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
|
Terlipressin acetate is a vasopressin analogue with potent vasoactive properties. Terlipressin acetate is a highly selective vasopressin V1 receptor agonist that reduces the splanchnic blood flow and portal pressure and controls acute variceal bleeding. Terlipressin acetate exerts anti-inflammatory and anti-oxidative effects. Terlipressin acetate has the potential for hepatorenal syndrome and norepinephrine-resistant septic shock research .
|
-
- HY-P2141A
-
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
TRV120027 TFA, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 TFA induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 TFA inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 TFA has the potential for the acute decompensated heart failure (ADHF) treatment .
|
-
- HY-P2141
-
|
Angiotensin Receptor
Arrestin
|
Cardiovascular Disease
|
TRV120027, a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1R), engages ß-arrestins while blocking G-protein signaling . TRV120027 induces acute catecholamine secretion through cation channel subfamily C3 (TRPC3) coupling, promotes the formation of a macromolecular complex composed of AT1R–β-arrestin-1–TRPC3–PLCγ at the plasma membrane. TRV120027 inhibits angiotensin II–mediated vasoconstriction and increases cardiomyocyte contractility. TRV120027 has the potential for the acute decompensated heart failure (ADHF) treatment .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0556AS
-
|
Tetrahydrozoline-d4 (hydrochloride) is the deuterium labeled Tetrahydrozoline hydrochloride. Tetrahydrozoline hydrochloride (Tetryzoline hydrochloride), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline hydrochloride is widely used for the research of nasal congestion and conjunctival congestion[1][2].
|
-
-
- HY-17034BS1
-
|
Medetomidine-13C,d3 (hydrochloride) is a deuterated labeled Medetomidine (hydrochloride) . Medetomidine hydrochloride is an orally active α2-adrenoceptor agonist (Ki: 1.08 nM). Medetomidine hydrochloride has sedative and analgesic effects. Medetomidine hydrochloride can cause peripheral vasoconstriction through the activation of α2 adrenoceptors on blood vessels .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: